T-cell therapies have emerged as an advancement in cancer treatment, with chimeric antigen receptor T (CAR-T) cell and T-cell receptor (TCR) therapies leading the way. These therapies harness the power of the immune system to target and destroy cancer cells more effectively. Beyond cancer, ongoing clinical research is investigating the potential of T-cell-based therapies for a variety of other conditions, which includes autoimmune diseases, infectious diseases, and transplantation.
As the demand for T-cells in medical applications continues to grow, the biopharmaceutical industry faces the critical task of developing robust production processes that ensure high-quality, aseptic T-cell manufacturing. Achieving optimal yields and high throughput is essential for maintaining cost efficiency and meeting the increasing demand. Moreover, the scalability of downstream processing platforms is crucial. It allows for the optimization of critical process parameters at a small scale before transitioning to commercial manufacturing. This scalability ensures that the production processes can be efficiently scaled up to meet larger demands without compromising quality.
Ksep® single-use counterflow centrifugation systems offer an effective and efficient solution for closed-cell processing, including concentration, washing, and harvesting. These systems provide dual functionality that supports both the harvest of cells as a product and the removal of cells for media harvest or clarification. The automated single-use design of Ksep® systems allows for processing cells within a closed unit using sterile disposables, which minimizes the risk of contamination and handling errors.
Access the full application note to learn more.